• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Wellington Hadley Harbor Aggregator Iv, L.P. converted options into 2,901,599 shares and bought $17,000,000 worth of shares (1,000,000 units at $17.00) (SEC Form 4)

    2/3/25 4:49:52 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care
    Get the next $BBNX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wellington Hadley Harbor Aggregator IV, L.P.

    (Last) (First) (Middle)
    C/O WELLINGTON MANAGEMENT COMPANY LLP
    280 CONGRESS STREET

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Beta Bionics, Inc. [ BBNX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/31/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 01/31/2025 C 2,901,599 A (1) 2,901,599 D
    Common Stock 01/31/2025 P 1,000,000(2) A $17 3,901,599 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Series E Preferred Stock (1) 01/31/2025 C 2,901,599 (1) (1) Common Stock 2,901,599 $0 0 D
    Explanation of Responses:
    1. Immediately prior to the closing of the initial public offering, each share of Series E Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.
    2. Shares acquired in a private placement pursuant to the terms of a Common Stock Purchase Agreement dated January 21, 2025.
    Wellington Hadley Harbor Aggregator IV, L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Jennifer C. Boylan, Authorized Person 02/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BBNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BBNX

    DatePrice TargetRatingAnalyst
    2/24/2025Buy
    BofA Securities
    2/24/2025$30.00Buy
    Lake Street
    2/24/2025$25.00Buy
    Stifel
    2/24/2025$26.00Overweight
    Piper Sandler
    2/24/2025$28.00Outperform
    Leerink Partners
    2/20/2025$20.00Neutral
    Ladenburg Thalmann
    2/20/2025$20.00Neutral
    Robert W. Baird
    More analyst ratings

    $BBNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Michel Gerard J was granted 12,547 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/27/25 7:04:55 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Michel Gerard J

      3 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/27/25 7:00:25 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Director Lezack Adam was granted 11,247 shares (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      3/18/25 8:00:11 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    $BBNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Product Officer Mensinger Mike bought $566,950 worth of shares (33,350 units at $17.00), converted options into 15,107 shares, exercised 10,575 in-the-money shares at a strike of $0.02 and sold $221 worth of shares (13 units at $17.00) (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      2/3/25 8:30:15 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Large owner Wellington Hadley Harbor Aggregator Iv, L.P. converted options into 2,901,599 shares and bought $17,000,000 worth of shares (1,000,000 units at $17.00) (SEC Form 4)

      4 - Beta Bionics, Inc. (0001674632) (Issuer)

      2/3/25 4:49:52 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    $BBNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025

      IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its annual guidance for the year ending December 31, 2025. First Quarter 2025 Financial Results & Key Metrics Net sales of $17.6 million, up 36% compared to $12.9 million in the first quarter of 2024. Durable Medical Equipment (DME) channel net sales of $13.8 million, up 14% compared to $12.1 million in the first quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $3.8 million, up 360% compared to $0.8 million in the first quarte

      5/6/25 4:02:00 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Present at the Bank of America Securities Health Care Conference

      IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at 12:35 pm Eastern Time (9:35 am Pacific Time). A live audio webcast of the presentation will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay following the event. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the desig

      5/1/25 8:00:00 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025

      IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. You may also access the live c

      4/16/25 4:05:00 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    $BBNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Beta Bionics

      BofA Securities initiated coverage of Beta Bionics with a rating of Buy

      2/24/25 1:34:43 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Beta Bionics with a new price target

      Lake Street initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $30.00

      2/24/25 9:48:29 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Beta Bionics with a new price target

      Stifel initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $25.00

      2/24/25 7:03:36 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care

    $BBNX
    Leadership Updates

    Live Leadership Updates

    See more

    $BBNX
    Financials

    Live finance-specific insights

    See more

    $BBNX
    SEC Filings

    See more
    • Beta Bionics Announces Board Appointment of Gerard Michel

      IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

      3/27/25 4:45:06 PM ET
      $BBNX
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025

      IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. You may also access the live c

      4/16/25 4:05:00 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

      IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived

      2/27/25 7:00:00 AM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Beta Bionics Inc.

      10-Q - Beta Bionics, Inc. (0001674632) (Filer)

      5/6/25 4:20:28 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Beta Bionics, Inc. (0001674632) (Filer)

      5/6/25 4:03:09 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Beta Bionics Inc.

      10-K/A - Beta Bionics, Inc. (0001674632) (Filer)

      3/28/25 4:05:42 PM ET
      $BBNX
      Medical/Dental Instruments
      Health Care